Elemento Lab

Publications

Found 145 results

Filters: First Letter Of Last Name is T [Clear All Filters]

2020

Beltran H, Romanel A, Conteduca V, Casiraghi N, Sigouros M, Franceschini GMarco, Orlando F, Fedrizzi T, Ku S-Y, Dann E et al.. 2020. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.. J Clin Invest. 130(4):1653-1668.

Vosoughi A, Zhang T, Shohdy KS, Vlachostergios PJ, Wilkes DC, Bhinder B, Tagawa ST, Nanus DM, Molina AM, Beltran H et al.. 2020. Common germline-somatic variant interactions in advanced urothelial cancer.. Nat Commun. 11(1):6195.

Marderstein AR, Uppal M, Verma A, Bhinder B, Tayyebi Z, Mezey J, Clark AG, Elemento O. 2020. Demographic and genetic factors influence the abundance of infiltrating immune cells in human tissues.. Nat Commun. 11(1):2213.

Liu H, Paddock MN, Wang H, Murphy CJ, Geck RC, Navarro AJ, Wulf GM, Elemento O, Haucke V, Cantley LC et al.. 2020. The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple-Negative Breast Cancer.. Cancer Discov. 10(8):1226-1239.

Liu D, Shoag JE, Poliak D, Goueli RS, Ravikumar V, Redmond D, Vosoughi A, Fontugne J, Pan H, Lee D et al.. 2020. Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes.. Nat Commun. 11(1):1987.

Han T, Goswami S, Hu Y, Tang F, Zafra MPaz, Murphy C, Cao Z, Poirier JT, Khurana E, Elemento O et al.. 2020. Lineage reversion drives WNT independence in intestinal cancer.. Cancer Discov.

Rendeiro AF, Casano J, Vorkas CKyriakos, Singh H, Morales A, DeSimone RA, Ellsworth GB, Soave R, Kapadia SN, Saito K et al.. 2020. Longitudinal immune profiling of mild and severe COVID-19 reveals innate and adaptive immune dysfunction and provides an early prediction tool for clinical progression.. medRxiv.

Shah MA, Enzinger P, Ko AH, Ocean AJ, Philip PAgop, Thakkar PV, Cleveland K, Lu Y, Kortmansky J, Christos PJ et al.. 2020. Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome.. Clin Cancer Res. 26(18):4756-4766.

Béguelin W, Teater M, Meydan C, Hoehn KB, Phillip JM, Soshnev AA, Venturutti L, Rivas MA, Calvo-Fernández MT, Gutierrez J et al.. 2020. Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response.. Cancer Cell. 37(5):655-673.e11.

Alsaleem MA, Ball G, Toss MS, Raafat S, Aleskandarany M, Joseph C, Ogden A, Bhattarai S, Rida PCG, Khani F et al.. 2020. A novel prognostic two-gene signature for triple negative breast cancer.. Mod Pathol.

Park K, Tran H, Eng KW, Ramazanoglu S, Rolon RMMarrero, Scognamiglio T, Borczuk A, Mosquera JMiguel, Pan Q, Sboner A et al.. 2020. Performance Characteristics of a Targeted Sequencing Platform for Simultaneous Detection of Single Nucleotide Variants, Insertions/Deletions, Copy Number Alterations, and Gene Fusions in Cancer Genome.. Arch Pathol Lab Med.

Ricker E, Verma A, Marullo R, Gupta S, Ye C, Pannellini T, Manni M, Tam W, Inghirami G, Elemento O et al.. 2020. Selective dysregulation of ROCK2 activity promotes aberrant transcriptional networks in ABC diffuse large B-cell lymphoma.. Sci Rep. 10(1):13094.

Conteduca V, Ku S-Y, Puca L, Slade M, Fernandez L, Hess J, Bareja R, Vlachostergios PJ, Sigouros M, Mosquera JMiguel et al.. 2020. SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy.. Mol Cancer Ther. 19(5):1157-1164.

Venturutti L, Teater M, Zhai A, Chadburn A, Babiker L, Kim D, Béguelin W, Lee TC, Kim Y, Chin CR et al.. 2020. TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate.. Cell. 182(2):297-316.e27.

Chu C-S, Hellmuth JC, Singh R, Ying H-Y, Skrabanek L, Teater MR, Doane AS, Elemento O, Melnick AM, Roeder RG. 2020. Unique Immune Cell Coactivators Specify Locus Control Region Function and Cell Stage.. Mol Cell. 80(5):845-861.e10.

2019

Conteduca V, Oromendia C, Eng KW, Bareja R, Sigouros M, Molina A, Faltas BM, Sboner A, Mosquera JMiguel, Elemento O et al.. 2019. Clinical features of neuroendocrine prostate cancer.. Eur J Cancer. 121:7-18.

Khosravi P, Kazemi E, Zhan Q, Malmsten JE, Toschi M, Zisimopoulos P, Sigaras A, Lavery S, Cooper LAD, Hickman C et al.. 2019. Deep learning enables robust assessment and selection of human blastocysts after in vitro fertilization.. NPJ Digit Med. 2:21.

Courtiol P, Maussion C, Moarii M, Pronier E, Pilcer S, Sefta M, Manceron P, Toldo S, Zaslavskiy M, Le Stang N et al.. 2019. Deep learning-based classification of mesothelioma improves prediction of patient outcome.. Nat Med. 25(10):1519-1525.

Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, Isse K, Kearney M, Vosoughi A, Fernandez L et al.. 2019. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.. Sci Transl Med. 11(484)

Rai R, Yadav SS, Pan H, Khan I, O'Connor J, Alshalalfa M, Davicioni E, Taioli E, Elemento O, Tewari AK et al.. 2019. Epigenetic analysis identifies factors driving racial disparity in prostate cancer.. Cancer Rep (Hoboken). 2(2):e1153.

Ma J, Redmond D, Miyaguchi A, Nam AS, Nie K, Mathew S, Elemento O, Tam W. 2019. Exploring tumor clonal evolution in bone marrow of patients with diffuse large B-cell lymphoma by deep IGH sequencing and its potential relevance in relapse.. Blood Cancer J. 9(9):69.